Breaking News

Aptuit Verona Site Gets 100th Client

November 9, 2012

Clients include companies from EU, North America, Asia and South America

The Aptuit Center for Drug Discovery & Development in Verona, Italy has reached its 100th client, according to Stuart Needleman, president and chief operating officer of Aptuit LLC. The Verona facility, which Aptuit bought from GSK in mid-2010, provides drug discovery and development services to large, multinational pharmaceutical companies, mid-sized and small pharma companies, biotechs and startups.
Mark Hembarsky, vice president and site leader of the facility, said, "We are excited to have reached this important milestone of 100 clients at Aptuit Verona. In July of 2010, we started with one client, GlaxoSmithKline, following our acquisition of the site from them. Since that time, more and more clients have been recognizing that we have something unique and valuable to offer, and that we are certainly doing something right in helping them achieve their goals."
"Companies from the EU, North America, Asia and South America have placed projects with us covering numerous therapeutic areas," Mr. Hembarsky added. "We are proud that industry-leading companies like Pfizer, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim, UCB, C10 Pharma, Autifony Therapeutics and GlaxoSmithKline, are among the clients that have chosen to partner with Aptuit."

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent